Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression

JCO Precis Oncol. 2024 Jun:8:e2300686. doi: 10.1200/PO.23.00686.

Ben L Kong¹, Jayne M Stommel¹, Jamie M Keck¹, David Kilburn^{1

2}, Aaron Streblow³, Julian Egger¹, Allison L Creason¹, Christopher G Suciu^{1

4}, Alexander R Guimaraes^{1

2

5}, Christopher L Corless^{1

4}, Gordon B Mills^{1

2}, Tanja B Pejovic¹

¹ Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
² Division of Oncological Sciences Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
³ Oregon Health & Science University School of Medicine, Portland, OR.
⁴ Department of Diagnostic Radiology, Oregon Health & Science University, Portland, OR.
⁵ Department of Pathology, Oregon Health & Science University, Portland, OR.

Abstract

Case report of a HER2-expressed ovarian clear cell carcinoma with exceptional response to trastuzumab deruxtecan.